One study of anti-PD-1 immunotherapy for 41 patients with various cancer types reported that PD-L2 expression was detected in 8 patients with renal cell carcinoma, melanoma, or NSCLC [24]. This evidence concerns the gene PDCD1LG2 and hereditary clear cell renal cell carcinoma.